TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of Participants With HIV RNA Levels <400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of solifenacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Natriuretic responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in ocular surface health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placement Time of Sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Urate (sUA) levels < 6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: success of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Anxiety Stress Scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Biologically confirmed tobacco cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Version of Cocaine Craving Questionnaire (Brief-CCQ) Total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cocaine consumption as assessed by Timeline Follow Back (TLFB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cocaine consumption as assessed by Urine Drug Screen (UDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of CUBICIN therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical response of CUBICIN therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cocaine Free Urine Toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-5 Toxicity Rate
Endpoint domain: Adverse events/effects
Primary endpoint: surgical completeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Modified Clinical Test of Sensory Integration for Balance (mCTSIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak anterior and superior hyoid movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parietal postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative intra abdominal complications
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Hemoglobin (Hgb) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in Serum Ferritin (SF) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Soluble Transferrin Receptor (sTfR) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Total Body Iron Stores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Onset of urinary peak flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Airway Sealing Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of delivering opt-out HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in caregiver resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of diffuse myocardial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nine-month Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in diet and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rating of vocal function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevention of rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Parkinson Anxiety Scale (PAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Twenty Five Foot Walk Test (25FWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Six-Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest drain output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain function/structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence and frequencies of CD4+ and CD8+ CD28null/NKG2Dpos T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in peak exercise pulmonary oxygen uptake (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in behavior for student 6-8 year measured with the Sutter-Eyberg Student Behavior Inventory-Revised (SESBI-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in behavior for student 6-8 year measured with the Teacher Report Form (TRF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in behavior for student 6-8 year measured with the Social Skills Rating System (SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Movement on iv placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved an Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kaplan Meier Estimate of Duration of Response (DoR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut Microbiome Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outcome in pediatric patients with systemic vasculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of proinflammatory molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days with diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Urinary Excretion of Mercapturic Acid of Benzene (4 Tablets)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary Excretion of Mercapturic Acid of Benzene (8 Tablets)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Epworth Sleepiness Score (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Serum Cortisol peak after low dose Synachten stimulation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in cerebral haemodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glycemic variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac Events (Composite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antibody Titers Against Varicella Zoster Virus (VZV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Concentrations Against Varicella Zoster Virus (VZV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post Traumatic Growth Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Best Corrected Visual Acuity (LogMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endothelial cell counts (cells/mm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Corneal keratometry measurement, Kmax(D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum 8-Hydroxy2-deoxyguanisine (8-OHdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspartate aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ɤ-glutamyltranspeptidase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance of deep cervical flexor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: microfibril fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Subfield Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Number of Reported Days-off Episodes Due to Infectious Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Number of Reported Episodes of Infectious Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrastructural abnormalities in muscle tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Myofiber atrophy in muscle tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6% With no Diabetes Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined end-point death/reinfarction/stroke
Endpoint domain: Mortality/survival
Primary endpoint: TIMI-flow <3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EF <30% on day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in the WHO ordinal scale of clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in decision-making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of health complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of dysphoric disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of platelet monocyte aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modified Rankin Scale (mRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: National Institute of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good neurological performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Transition Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (CR + PR by RECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in faecal incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percentage of daily sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative and quantitative toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrasound measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Patients Who Respond to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic and mucosal safety
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of orientation program and follow-up care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PROMIS Depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in PROMIS Anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in FACT-G scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of subjects with any adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: patterns of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Completion of surveys
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Plasma Concentration Vs Time Curve (AUC) of FG-3019
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Human Anti-human Antibody (HAHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained Virologic Response at Follow-Up Week 24 (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (AEs) Leading to Dose Modification or Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Neutrophil Count <0.75 × 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin (Hgb) <10 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response to Composite Endpoint of ALP and Total Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined allergy symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance to Palmar Crease Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cigarette smoke retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient's pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Impact
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Breathing style
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention-related knowledge and beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Service-seeking intent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Siel Bleu balance exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety profile of LAMB treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary heart disease risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dimensions of diabetic foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Activation During Response Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration from labor induction to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Coronary bypass graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in brain derived neurotrophic factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Static pain at 30 minutes after arrival in the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical patency of the hemodialysis extracorporeal circuit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from Atrial Fibrillation (AF) Recurrence at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from Atrial Arrhythmia at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from Arrythmias at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from Device / Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Binding of the PET probe [11C]PBR28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of visits associated with antibiotic prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chest tube duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain severity at 24 hrs post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Forced Expiratory Volume (FEV1) AUC 0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of stent-strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of perioperative spinal induced shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Inflammatory Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Proliferative Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing Evaluation Using Inflammatory-Proliferative-Remodelling Scale (IPR Scale): Remodelling Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point prevalence smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICP pulse waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICP pulse waveform 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Experienced ≥30% Reduction in Average Low Back Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic or Clinical Relapse at 30 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Nasal polyposis quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nasal patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum plasma doxorubicin concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: areas under the plasma concentration versus time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: areas under the plasma concentration versus time curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle amino acid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shift in iron isotopic composition in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) from 0 to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ipatasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic concentration in subsequently collected samples from the same patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Creatinine Clearance at 1 Month After Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine Clearance at Month 6 After Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes